Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD

Absci a clinical-stage biotech company advancing novel therapeutics with generative AI, today announced a collaboration with Oracle Cloud Infrastructure (OCI) and AMD to accelerate generative AI-driven drug discovery. Absci's generative AI Drug Creation Platform leverages OCI's AI infrastructure and AMD's latest hardware, enabling it to consolidate its infrastructure and accelerate its biologics design cycles.

To advance Absci's mission of creating better biologics for patients more quickly, Absci has selected OCI as the technical foundation for developing AI models and scaling AI workflows. With OCI, Absci has been able to accelerate the development and operations of its AI Drug Creation Platform, including large‑scale molecular‑dynamics (MD) simulations and end‑to‑end antibody design. Absci is building on this success with OCI and partnering with AMD to further boost the performance and scalability of its AI Drug Creation Platform with AMD's next generation Instinct™ MI355X GPUs.

"Our mission is to push the boundaries of how we design new therapeutics," said Sean McClain, Founder and CEO, Absci. "With OCI and AMD, we are pairing our cutting-edge AI models with best‑in‑class infrastructure. This collaboration accelerates our ability to bring novel therapeutics to patients while laying the technical foundation for the next generation of AI‑powered drug‑discovery workflows."

Scaling AI-driven drug discovery with OCI and AMD

OCI's bare metal instances, powered by 5th Generation AMD EPYC™ processors and ultrafast RDMA cluster networking, give Absci the low-latency networking and throughput needed for large-scale model training and high-resolution molecular-dynamics simulations that refine antibody–antigen interactions. With direct, bare-metal access to AMD GPUs in a single, flat-network supercluster, Absci has been able to eliminate hypervisor overhead, reduce inter-GPU latency to as little as 2.5 µs, and benefit from terabytes-per-second throughput for checkpointing and data streaming.

"Absci's generative AI-driven drug discovery is the kind of breakthrough workflow OCI was built for," said Dan Spellman, vice president, AI and OCI, Healthcare & Life Sciences, Oracle. "By combining bare metal GPUs, OCI Compute E6 instances, ultrafast RDMA networking, and high-performance storage, we're providing the predictable performance and close engineering collaboration Absci needs to push the boundaries of biologics design."

"Absci is demonstrating how AI can transform the pace of drug discovery, and we're proud to support that mission," said Ram Peddibhotla, corporate vice president, Data Center GPU Cloud Business, AMD. "By combining OCI with AMD EPYC CPUs, AMD Instinct GPUs and our open ROCm software platform, this collaboration provides the performance and scalability needed to advance complex biologics design and support more efficient discovery workflows."

About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci's approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Absci is headquartered in Vancouver, WA, with an AI Research Lab in New York City, and Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn ( @absci ), X ( @Abscibio ) and YouTube .

About AMD
For more than 55 years AMD has driven innovation in high-performance computing, graphics and visualization technologies. Billions of people, leading Fortune 500 businesses and cutting-edge scientific research institutions around the world rely on AMD technology daily to improve how they live, work and play. AMD employees are focused on building leadership high-performance and adaptive products that push the boundaries of what is possible. For more information about how AMD is enabling today and inspiring tomorrow, visit the AMD (NASDAQ:AMD) website , blog , LinkedIn , Facebook and X pages.

About Oracle
Oracle offers integrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud. For more information about Oracle (NYSE: ORCL), please visit us at www.oracle.com .

Trademarks
AMD, EPYC, AMD Instinct, ROCm and combinations thereof are trademarks of Advanced Micro Devices, Inc. Other names are for informational purposes only and may be trademarks of their respective owners.

Oracle, Java, MySQL and NetSuite are registered trademarks of Oracle Corporation. NetSuite was the first cloud company—ushering in the new era of cloud computing.

Contact Info
Absci
press@absci.com

David Szabados
AMD Communications
david.szabados@amd.com

Julia Allyn
Oracle
julia.allyn@oracle.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

AMD
The Conversation (0)
Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Mr. John Bathery to its Board of Directors,... Keep Reading...
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration Cash of $11.1M to support pharmaceutical developments into the fourth... Keep Reading...
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025... Keep Reading...
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and a significant safety marginDose ranging studies completed InMed Pharmaceuticals Inc. (NASDAQ:... Keep Reading...
Cisco Live 2024: Cisco Announces New AI-powered Innovations and Investments to Help Customers Unlock a More Connected and Secure Future

Cisco Live 2024: Cisco Announces New AI-powered Innovations and Investments to Help Customers Unlock a More Connected and Secure Future

News summary: AI-powered innovations build customers' digital resilience by uniquely combining the power of the network with industry-leading security, observability, and data, simplifying adoption, and offering visibility and insight across the entire digital footprint. Cisco Investments has... Keep Reading...
Stock chart overlay on a laptop keyboard symbolizes rising market trends.

Tech Weekly: Cloud Providers, Tech Stocks Outperform as Earnings Season Rolls On

Welcome to the Investing News Network's weekly round-up of the top tech news and biggest tech stocks driving the markets. Plus, we break down next week's market catalysts to watch to help you prepare for the week ahead.Don't forget to follow us @INN_Technology for real-time news... Keep Reading...
Homerun Resources Inc. Financings Update

Homerun Resources Inc. Financings Update

Homerun Resources Inc. (TSXV: HMR,OTC:HMRFF) (OTCQB: HMRFF) ("Homerun" or the "Company") announces that the Company has submitted its formal application for conditional approval of the previously announced $6-million financing with a single institutional investor. The Company is now awaiting... Keep Reading...
Torchlight Innovations Inc.  Opens the Market

Torchlight Innovations Inc. Opens the Market

Duane Nelson, President and Chief Executive Officer, Torchlight Innovations Inc. (TSXV: RZL) ("Company"), and its executive management team, joined Omar Khafagy, Head Client Success, Toronto Stock Exchange ("TSX"), to open the market and celebrate the Company's new listing on TSX Venture... Keep Reading...
Westport to Issue Q3 2025 Financial Results on November 10, 2025

Westport to Issue Q3 2025 Financial Results on November 10, 2025

Westport Fuel Systems Inc. (TSX: WPRT Nasdaq: WPRT) ("Westport" or "The Company") announces that the Company will release Q3 2025 financial results on Monday, November 10, 2025, after market close. A conference call and webcast to discuss the financial results and other corporate developments... Keep Reading...
CHARBONE Announces a Strategic Alliance with a Leading U.S. Industrial Gas Producer

CHARBONE Announces a Strategic Alliance with a Leading U.S. Industrial Gas Producer

(TheNewswire) Brossard, Quebec, October 20, 2025 TheNewswire - CHARBONE CORPORATION (TSXV: CH,OTC:CHHYF; OTCQB: CHHYF; FSE: K47) (" CHARBONE " or the " Company "), a North American producer and distributor specializing in clean Ultra High Purity (" UHP ") hydrogen and strategic industrial gases... Keep Reading...
CHARBONE annonce une alliance strategique avec un important producteur de gaz industriel americain

CHARBONE annonce une alliance strategique avec un important producteur de gaz industriel americain

(TheNewswire) Brossard, Quebec TheNewswire - le 20 octobre 2025 CORPORATION CHARBONE (TSXV: CH,OTC:CHHYF; OTCQB: CHHYF; FSE: K47) (« CHARBONE » ou la « Société »), un producteur et distributeur nord-américain spécialisé dans l'hydrogène propre à Ultra Haute Pureté (« UHP ») et les gaz... Keep Reading...

Latest Press Releases

Related News